Wells Fargo & Company Mereo Biopharma Group PLC Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Wells Fargo & Company holds 229 shares of MREO stock, worth $435. This represents 0.0% of its overall portfolio holdings.
Number of Shares
229
Previous 230
0.43%
Holding current value
$435
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding MREO
# of Institutions
98Shares Held
117MCall Options Held
151KPut Options Held
455K-
Janus Henderson Group PLC London, X017.1MShares$32.5 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$29.1 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$18.2 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$16.6 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.64MShares$16.4 Million4.71% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $237M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...